PD-L1 SP142 FDA (TECENTRIQ®) for NSCLC
Also known as: PD-L1, SP142
Companion Diagnostic
PD-L1 SP142 FDA (TECENTRIQ®) for NSCLC is an FDA-approved companion diagnostic used to help identify patients who may be eligible for targeted therapies.
Use
The VENTANA PD-L1 (SP142) Assay is a qualitative immunohistochemical assay intended for use in the assessment of the PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue. Evaluation is based on the proportion of tumor area occupied by PD-L1 expressing tumor-infiltrating immune cells (% IC) or PD-L1 expressing tumor cells (% TC).
Special Instructions
Not provided.
Limitations
Tissue submitted must have 50 viable tumor cells present. Block and slide identifiers should be clearly written and match exactly with the specimen ID and labeling as noted on the requisition.
FDA ApprovedNew York ApprovedCompanion Diagnostic
Methodology
Immunoassay (IHC)
Biomarkers
PD-L1
Protein
LOINC Codes
- 83057-0 - PD-L1 by SP142 Tiss Ql ImStn
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Storage Instructions
Use cold pack for transport, making sure cold pack is not in direct contact with specimen.